Giuliano Marostica

Giuliano Marostica is Managing Partner at TCGX, a leading healthcare investment firm based in New York, NY, where he plays a central role in building the firm and delivering value to portfolio companies. He leads investments across both private and public sectors, with a specific focus on life sciences and biotechnology companies developing disruptive medicines and innovative therapies in areas such as therapeutics and oncology.

Before stepping into his current leadership position, Giuliano was Principal at TCGX and previously served as a Senior Associate at Great Point Partners, concentrating on public investments in therapeutics firms. Earlier in his career, he worked as an analyst in the Healthcare Investment Banking group at Citigroup, gaining exposure to the broader healthcare financial landscape.

Giuliano holds a Bachelor of Science in Biomedical Engineering from Brown University, graduating magna cum laude. Notable achievements include leading investments in CG Oncology (NASDAQ: CGON), Chinook (acquired by Novartis), Cymabay (acquired by Gilead), Inhibrx (acquired by Sanofi), and Madrigal Pharmaceuticals, exemplifying his expertise and impact in the biotech investment sector.